Sponsors › Sanofi
Sanofi
Every GLP‑1 and incretin trial, approval and scheduled result we hold for Sanofi, drawn from ClinicalTrials.gov and Drugs@FDA.
Sanofi is a commercial sponsor with 44 trials in the incretin class on file here, across 4 molecules. The programme is split between 6 early-stage trials and 38 in phase 3 or later. No approved FDA submission is recorded against this sponsor for these molecules, which is normal for a programme that has not reached the market.
- Molecules
- dulaglutide · exenatide · liraglutide · lixisenatide
- Trials on file
- 44
- Active trials
- 1
- Results scheduled
- 0
- Approved FDA submissions
- 0
Trials on file
All 44 incretin trials recorded for this sponsor, active first.